Emerging systemic therapies for atopic dermatitis: oral small molecules and targeted topical agents

References

• Hanifin J, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11–18.
   PubMed Web of Science ®Google Scholar
• Futamura M, Leshem YA, Thomas KS, et al. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74(2):288–294.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Reaney M, Mastey V, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–769.
   PubMed Web of Science ®Google Scholar
• Heinl D, Prinsen C, Deckert S, et al. Measurement properties of adult quality‐of‐life measurement instruments for eczema: a systematic review. Allergy. 2016;71(3):358–370.
   PubMed Web of Science ®Google Scholar
• Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):e24137.
   PubMedGoogle Scholar
• Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak–STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384.
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28(4):477–487.
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542–550.
   PubMed Web of Science ®Google Scholar
• Shimoda K, van Deursen J, Sangster MY, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted State6 gene. Nature. 1996;380(6575):630–633.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. JI. 2010;184(9):5298–5307.
   Google Scholar
• Simpson E, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Sinclair R, Forman S, editors. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the Phase 3, JADE-MONO-1 Study. Oral presentation at the 28th Congress of the European Academy of Dermatology and Venereology (EADV); 2019; Madrid, Spain.
   Google Scholar
• Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863.
   PubMed Web of Science ®Google Scholar
• Simpson E, Sinclair R, Forman S, et al., editors. Efficacy and Safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the Phase 3 JADE MONO-1 Study. Poster presented at: European Academy of Dermatology and Venereology 28th Congress; 2019 October 9–13; Madrid, Spain.
   Google Scholar
• Guttman-Yassky E, Anderson J, Pangan A, et al., editors. Primary results from a phase 2b, randomized, placebo-controlled trial of upadacitinib for patients with atopic dermatitis. San Diego (CA): American Academy of Dermatology Annual Meeting; 2018.
   Google Scholar
• RINVOQ™ (upadacitinib) monotherapy shows improvement in skin clearance and itch in first phase 3 study for atopic dermatitis. North Chicago (IL): Abbvie News Center. 2020 Jun 18.
   Google Scholar
• Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109–3117.
   PubMed Web of Science ®Google Scholar
• Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145(2):572–582.
   PubMed Web of Science ®Google Scholar
• Incyte announces positive topline results from phase 3 TRuE-AD program evaluating ruxolitinib cream in patients with atopic dermatitis [Internet]. Wilmington (Delaware): Incyte News; [cited 2020 Feb 19].
   Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2020;47(2):114–120.
   PubMed Web of Science ®Google Scholar
• Schafer P, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signalling. 2014;26(9):2016–2029.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Imafuku S, Poulin Y, et al. A phase 2 randomized trial of apremilast in patients with atopic dermatitis. J Invest Dermatol. 2019;139(5):1063–1072.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Spuls PI, Thomas KS, HOME initiative orators, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4):800–807.
   PubMed Web of Science ®Google Scholar